Drug General Information (ID: DDI179VR2S)
Drug Name			Abarelix		Drug Info		Thioridazine		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antineoplastics				Antipsychotic Agents
Structure

Mechanism of Abarelix-Thioridazine Interaction (Severity Level: Major)
Increased risk of prolong QT interval Click to Show/Hide Mechanism Graph
Drug Name		Abarelix				Thioridazine
Mechanism		Prolong QT interval				Prolong QT interval
Key Mechanism Factor 1
		Factor Name		QT interval
		Factor Description		Long QT syndrome is a heart signaling disorder that can cause a fast, chaotic heartbeat (arrhythmia). Many people may not exhibit symptoms, and usually the condition is detected during routine medical tests. In others, the most common symptoms include: sudden fainting, palpitations, dizziness, seizures, sudden death.
Mechanism Description		Increased risk of prolong QT interval by the combination of Abarelix and Thioridazine

Recommended Action
Management		Coadministration of thioridazine with other drugs that can prolong the QT interval is considered contraindicated.

References
1	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
2	Liberatore MA, Robinson DS "Torsade de pointes: a mechanism for sudden death associated with neuroleptic drug therapy?" J Clin Psychopharmacol 4 (1984): 143-6. [PMID: 6145728]
3	Product Information. Mellaril (thioridazine). Sandoz Pharmaceuticals Corporation, East Hanover, NJ.